Adenosine vs Diltiazem for SVT in the ED
This study is looking at two common medications, adenosine and diltiazem, to treat a fast heart rhythm called supraventricular tachycardia (SVT) in adults who come to the emergency department. The main goal is to understand how patients feel about these treatments. You might be able to join if you are 18 or older and have SVT. The study aims to enroll 20 people and is currently unclear if it's recruiting. Success for this study means understanding patient perceptions of these treatments within 24 hours of starting.
- Study design
- This is a small pilot study aiming to enroll 20 adult participants. It compares two interventions: adenosine and diltiazem.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed from enrollment until the end of their emergency department visit, up to 24 hours.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Adenosine vs Diltiazem for Treatment of SVT in the ED
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Anne Zepeski, PharmD · PRINCIPAL_INVESTIGATOR · University of Iowa
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Feasibility outcomeFrom enrollment to the end of ED encounter (up to 24 hours).
Patients with stable SVT are identified in the ED (Threshold \>90%)
- Feasibility outcomeFrom enrollment to the end of ED encounter (up to 24 hours).
Eligible participants who provide consent to participate (Threshold \>50%)
- Feasibility outcomeFrom enrollment to the end of ED encounter (up to 24 hours).
Participants who complete all study procedures (Threshold \>80%)